Narrowband UVB phototherapy is a well-established, evidence-based treatment for several chronic skin conditions — primarily psoriasis, atopic dermatitis, and vitiligo. It uses a specific 311-313 nanometer band of ultraviolet B light identified as the most therapeutically active range for these conditions, while minimizing exposure to the broader UV spectrum associated with higher risks of erythema and long-term skin damage.
Phototherapy has been used to treat skin disease for decades, and NBUVB specifically has an extensive and favorable safety and efficacy record. For patients with moderate to severe psoriasis or atopic eczema who are on the fence about systemic medications, or who cannot use systemic treatments due to other health considerations, NBUVB offers a meaningful alternative. For vitiligo, it remains the most effective treatment for repigmentation available.
How it works
Treatments are performed in our office in a light therapy unit. Sessions are brief — often only a few minutes, increasing gradually as the protocol progresses — and scheduled two to three times per week. A standard treatment course runs six to twelve weeks, with clinical assessment throughout to evaluate response and adjust dosing.
We start at a dose calibrated to the patient’s skin type and photosensitivity, and increase incrementally based on response and tolerance. The light suppresses the overactive immune responses that drive psoriasis and eczema, and stimulates the migration of pigment-producing melanocytes into depigmented patches in vitiligo. Overexposure produces a sunburn-like reaction — the primary side effect we monitor to avoid.
Conditions treated
Plaque psoriasis, particularly involving large surface areas where topical treatment becomes impractical, responds very well to NBUVB. Many patients achieve 75 percent or greater improvement in disease severity with a full treatment course.
Atopic dermatitis that is widespread, chronic, and incompletely controlled with topical therapy is an appropriate indication. NBUVB can reduce itch and inflammation significantly and is particularly useful for patients who prefer to minimize or delay biologic therapy.
Vitiligo treatment with NBUVB produces repigmentation in a substantial proportion of patients, particularly when started relatively early after disease onset and when the affected areas have good follicular density. It requires a commitment to regular treatment over an extended period and produces gradual results.
Other inflammatory conditions including early-stage mycosis fungoides (cutaneous T-cell lymphoma), lichen planus, and prurigo nodularis may also respond to NBUVB.
Frequently asked questions
How is this different from tanning beds?
Tanning beds primarily emit UVA light, in uncontrolled doses. NBUVB delivers a specific, narrow wavelength of UVB light in precisely calibrated doses. The mechanism, efficacy, and safety profile are completely different. Tanning beds don’t provide therapeutic benefit for psoriasis or eczema and carry significant carcinogenic risk with regular use.
Does it increase skin cancer risk?
The long-term carcinogenic risk of NBUVB appears low compared to older modalities like PUVA, which has a well-documented association with squamous cell carcinoma. We track cumulative dose and discuss the risk profile in the context of each patient’s skin cancer history and risk factors.
Can I do this if I’m on other medications?
Some medications increase photosensitivity. We review your current medications before starting treatment and advise on what to continue, pause, or adjust so the combination works effectively rather than against itself.
What if I miss sessions?
Consistency matters. Frequent missed sessions interrupt the treatment response and may require restarting the dosing progression. Real life means occasional missed sessions are unavoidable, but maintaining the schedule as closely as possible produces substantially better outcomes.